Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore

      Cipla acquires 4 key brands from Wanbury for up to Rs 89 crore

      Medical Dialogues Bureau10 Feb 2020 8:00 PM IST
      New Delhi: Drug firm Cipla on Saturday said it has acquiredfourbrandsfrom Wanbury Ltdto strengthen its presence in the women's health segment. ...
      Pfizer Oncology biosimilar Ruxience gets positive opinion from CHMP

      Pfizer Oncology biosimilar Ruxience gets positive opinion from CHMP

      Medical Dialogues Bureau9 Feb 2020 9:30 AM IST
      New York: Pfizer Inc. recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
      Alkem Labs St Louis facility gets 3 USFDA observations

      Alkem Labs St Louis facility gets 3 USFDA observations

      Medical Dialogues Bureau8 Feb 2020 4:13 PM IST
      New Delhi: Drugmaker Alkem Laboratories (Alkem Labs) recently informed that the company has received three observations from the US health...
      Granules Pharma gets USFDA nod for genetic disorder drug Colchicine

      Granules Pharma gets USFDA nod for genetic disorder drug Colchicine

      Medical Dialogues Bureau8 Feb 2020 10:30 AM IST
      "The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc, a...
      Lupin posts net loss at Rs 835 crore in Q3

      Lupin posts net loss at Rs 835 crore in Q3

      Medical Dialogues Bureau8 Feb 2020 10:15 AM IST
      New Delhi: Pharma firm Lupin on Thursday reported widening of its consolidated net loss to Rs 835 crore for the quarter ended December 2019 on account...
      AbbVie gets positive CHMP Opinion for VENCLYXTO for Leukemia patients

      AbbVie gets positive CHMP Opinion for VENCLYXTO for Leukemia patients

      Medical Dialogues Bureau8 Feb 2020 10:00 AM IST
      New Delhi: AbbVie , a research-based global biopharmaceutical company, announced recently that the Committee for Medicinal Products for Human Use...
      GSK India to sell Vemgal facility

      GSK India to sell Vemgal facility

      Medical Dialogues Bureau8 Feb 2020 9:30 AM IST
      As part of this strategic review, GSK India will explore future options for the Vemgal facility including a potential sale of the site, it added. ...
      Regeneron partners with US to develop treatment for coronavirus

      Regeneron partners with US to develop treatment for coronavirus

      Medical Dialogues Bureau7 Feb 2020 9:30 AM IST
      US: The United States is working with a pharmaceutical company to develop a treatment for the 2019 Novel Coronavirus, using a class of drug that has...
      Merck to spin-off  biosimilar drugs business to focus on Keytruda

      Merck to spin-off biosimilar drugs business to focus on Keytruda

      Medical Dialogues Bureau7 Feb 2020 9:15 AM IST
      Merck will retain its cancer drugs, including blockbuster cancer therapy Keytruda, vaccines, hospital and animal health businesses, the company...
      Lupin gets USFDA nod for generic version of Arava Tablets

      Lupin gets USFDA nod for generic version of Arava Tablets

      Medical Dialogues Bureau6 Feb 2020 1:08 PM IST
      Leflunomide Tablets USP is a generic equivalent of Arava Tablets, 10 mg and 20 mg, of Sanofi- Aventis, Lupin said.Mumbai: Pharma major Lupin Limited...
      Granules India sells entire stake in JV Biocause Pharma

      Granules India sells entire stake in JV Biocause Pharma

      Medical Dialogues Bureau6 Feb 2020 1:00 PM IST
      New Delhi: Drugmaker Granules India Ltd recently said it has divested its entire stake in Granules-Biocause Pharmaceutical Co Limited, a...
      Cipla Q3 revenue up by 13pc at Rs 4371 crore

      Cipla Q3 revenue up by 13pc at Rs 4371 crore

      Medical Dialogues Bureau6 Feb 2020 12:30 PM IST
      "We have had yet another good quarter: India business continued its momentum with strong double-digit growth in the prescription business; growth...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok